Patents by Inventor Nick Knudsen

Nick Knudsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 9567386
    Abstract: Modified relaxin polypeptides and their uses, including therapeutic uses thereof for the treatment of a fibrotic disorder or heart failure are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 14, 2017
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine de Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20170035897
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9517273
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: December 13, 2016
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 9452222
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • MODIFIED CANINE LEPTIN POLYPEPTIDES
    Publication number: 20150366983
    Abstract: Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 24, 2015
    Inventors: Michael BLEDSOE, Peter Connor CANNING, Michael DEGUZMAN, Nick KNUDSEN, Ianina VALENTA
  • Modified Insulin Polypeptides and Their Uses
    Publication number: 20150299288
    Abstract: Modified insulin polypeptides and their uses thereof are provided
    Type: Application
    Filed: December 19, 2014
    Publication date: October 22, 2015
    Applicant: AMBRX, INC.
    Inventors: Zhenwei MIAO, Denise KRAWITZ, Vadim KRAYNOV, Tian FENG, Bee-Cheng SIM, Lillian SKIDMORE, Anna-Maria A. HAYS PUTNAM, Nick KNUDSEN, Michael DEGUZMAN
  • THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS
    Publication number: 20150273075
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 1, 2015
    Inventors: Thomas P. CUJEC, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9079971
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: July 14, 2015
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Ho, Jason Pinkstaff, Vadim Kraynov
  • Prostate-Specific Membrane Antigen Antibody Drug Conjugates
    Publication number: 20150152190
    Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: June 7, 2013
    Publication date: June 4, 2015
    Applicant: Ambrx, Inc.
    Inventors: Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
  • Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
    Publication number: 20150152187
    Abstract: This invention relates to anti-prostate-specific membrane antigen antibodies (?PSMA) and ?PSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 4, 2015
    Applicant: Ambrx, Inc.
    Inventors: Ying Sun, Ning Zou, Amha Hewet, Jason K. Pinkstaff, Shailaja Srinagesh, Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck
  • Anti-CD70 Antibody Drug Conjugates
    Publication number: 20150141624
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 21, 2015
    Applicant: AMBRX, INC.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason K. Pinkstaff
  • Modified insulin polypeptides and their uses
    Patent number: 8946148
    Abstract: Modified insulin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: February 3, 2015
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Denise Krawitz, Vadim Kraynov, Feng Tian, Bee-Cheng Sim, Lillian Skidmore, Anna-Maria A. Hays Putnam, Nick Knudsen, Michael Deguzman
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20140194357
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: AMBRX, INC.
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AHMA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8735539
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: May 27, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8691940
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 8, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
    Publication number: 20130237481
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 12, 2013
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine de Dios, Jason Pinkstaff, Lorraine Sullivan
  • Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
    Patent number: 8383365
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 26, 2013
    Assignee: AMBRX, Inc.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore (Nee Ho), Jason Pinkstaff, Vadim Kraynov
  • Modified interferon beta polypeptides and their uses
    Patent number: 8329869
    Abstract: Modified interferon beta polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: December 11, 2012
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Anna-Maria A. Hays Putnam, Denise Krawitz, Jason Pinkstaff, Heather Myler
  • MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
    Publication number: 20120283172
    Abstract: Modified porcine somatotropin polypeptides and uses thereof are provided.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 8, 2012
    Applicant: AMBRX, INC.
    Inventors: John W. Wallen, III, Nick Knudsen, Vadim Kraynov
  • MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES
    Publication number: 20120197006
    Abstract: Modified interferon beta polypeptides and uses thereof are provided.
    Type: Application
    Filed: January 6, 2012
    Publication date: August 2, 2012
    Applicant: AMBRX, INC.
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Anna-Maria A. HAYS PUTNAM, Denise KRAWITZ, Jason PINKSTAFF, Heather MYLER